Medical News

RSS

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

4 Aug 2010

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.

4 Aug 2010

Biomedical engineering professor receives patent for Electromagnetic Probe Device

The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.

4 Aug 2010

Researchers discover first combined device for probing, detecting DNA

DNA microarrays are one of the most powerful tools in molecular biology today. The devices, which can be used to probe biological samples and detect particular genes or genetic sequences, are employed in everything from forensic analysis to disease detection to drug development.

4 Aug 2010

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

4 Aug 2010

Judge gives the go-ahead to Virginia's health overhaul challenge

In a ruling issued Monday, U.S. District Judge Henry Hudson refused to dismiss the lawsuit filed by Virginia challenging a key aspect of the health care overhaul. The next round of arguments in this case is scheduled for October.

4 Aug 2010

Study analyzes prevalence of pediatric patient-safety events at hospitals

Hospital-acquired infections are the leading cause of potentially preventable mortality among pediatric patients, according to a study of pediatric patient-safety incidents issued today by HealthGrades, the leading independent health care ratings organization.

4 Aug 2010

Horizon Pharma files registration statement with U.S. SEC for proposed initial public offering

Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

4 Aug 2010

Sensory dysfunction affects quality of life of patients with Autism

The way the brain reacts differently to the sense of touch in people with Autism will be examined as part of an innovative Cardiff University study designed to create better understanding of the condition. Dr David McGonigle from Cardiff University's Schools of Psychology and Biosciences will use the latest brain imaging techniques to create a clearer picture of how touch is processed differently.

4 Aug 2010

GTCR, Dale Wolf partner to create Jessamine Healthcare

GTCR, one of the nation's leading private equity firms, today announced it has entered into a partnership with Dale Wolf to form Jessamine Healthcare, Inc. The new company, headquartered in Rockville, Maryland, will focus on acquiring companies in the healthcare payor and outsourced payor services industries.

4 Aug 2010

GE and Intel create new health IT venture focused on home-based care

General Electric Co. and Intel Corp. announced Monday they will create a company to provide new medical technologies for the elderly and chronically ill.

4 Aug 2010

Foreign doctors provide care as good as that of Americans, study finds

Physicians trained in other countries provide care just as good as -- and perhaps better than some U.S. doctors, a report published in the journal Health Affairs found.

4 Aug 2010

Spectrum Health selects Aternity FPI Platform for strategic end user experience management initiatives

Aternity Inc., the industry's technology leader in end user experience management solutions for Global 1000 enterprises, announced today that Spectrum Health, a not-for-profit health system in West Michigan that offers a full continuum of care that includes the Spectrum Health Hospital Group, has selected the Aternity Frontline Performance Intelligence (FPI) Platform for its strategic end user experience management initiatives.

4 Aug 2010

Research findings show normal rise and fall in triglycerides

When the circadian rhythm gets thrown off, it could come with an unexpected side effect: high triglycerides. The discovery, based on studies in mice with a "broken clock," helps to explain the normal rise and fall in triglycerides, which happens at about the same time each day, according to researchers who report their findings in the August issue of Cell Metabolism, a Cell Press publication.

4 Aug 2010

CRICO/RMF achieves highest level of accreditation

CRICO/RMF has been awarded the highest level of accreditation, "Accreditation with Commendation," as a provider of Continuing Medical Education for physicians. This six-year accreditation is the result of an extensive (re)survey by the Accreditation Council for Continuing Medical Education in which CRICO/RMF demonstrated compliance in all 22 of its criteria.

4 Aug 2010

New algorithm to reduce radiation dose in CT imaging

In recent years, advances in CT scanner technology have made perfusion computed tomography (CT) imaging an important diagnostic tool for patients with suspected stroke. Now, researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images. Mayo Clinic medical physicist Cynthia McCollough, Ph.D., and her group of researchers presented their findings related to CT dose reduction at the 52nd Annual Meeting of the American Association of Physicists in Medicine on July 20 in Philadelphia. The presentation was entitled "20-Fold Dose Reduction Using a Gradient Adaptive Bilateral Filter: Demonstration Using in Vivo Animal Perfusion CT."

4 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

BARDA awards contract to develop Pfenex Expression Technology

Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.

4 Aug 2010

DTB launches Don't Drop Mixtard 30 campaign to change Novo Nordisk's drug removal decision

Drug company Novo Nordisk's decision to pull its Mixtard 30 insulin drug from the UK could add 9 million to the NHS drugs bill in England alone, says an editorial in the Drug and Therapeutics Bulletin (DTB). The decision could also leave thousands of patients dependent on others to help them take their insulin, says DTB, which today launches its "Don't Drop Mixtard 30" campaign to convince the company to change its mind.

4 Aug 2010

Administration touts Medicare savings report; Republicans complain it misleads seniors

A report issued Monday by the Obama administration found that the new health care law "will save Medicare $8 billion by the end of 2011, and $575 billion over the next decade, largely by improving care quality and preventing waste and fraud." The report also predicts that the overhaul will "extend the life of the program more than a decade.

4 Aug 2010

Medical News

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Biomedical engineering professor receives patent for Electromagnetic Probe Device

Researchers discover first combined device for probing, detecting DNA

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Judge gives the go-ahead to Virginia's health overhaul challenge

Study analyzes prevalence of pediatric patient-safety events at hospitals

Horizon Pharma files registration statement with U.S. SEC for proposed initial public offering

Sensory dysfunction affects quality of life of patients with Autism

GTCR, Dale Wolf partner to create Jessamine Healthcare

GE and Intel create new health IT venture focused on home-based care

Foreign doctors provide care as good as that of Americans, study finds

Spectrum Health selects Aternity FPI Platform for strategic end user experience management initiatives

Research findings show normal rise and fall in triglycerides

CRICO/RMF achieves highest level of accreditation

New algorithm to reduce radiation dose in CT imaging

Arcelis immunotherapy effective in treating autoimmune diseases: Study

BARDA awards contract to develop Pfenex Expression Technology

DTB launches Don't Drop Mixtard 30 campaign to change Novo Nordisk's drug removal decision

Administration touts Medicare savings report; Republicans complain it misleads seniors

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News